KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Retained Earnings (2016 - 2025)

Sarepta Therapeutics has reported Retained Earnings over the past 15 years, most recently at $272000.0 for Q4 2025.

  • Quarterly results put Retained Earnings at $272000.0 for Q4 2025, up 224.77% from a year ago — trailing twelve months through Dec 2025 was $272000.0 (up 224.77% YoY), and the annual figure for FY2025 was $272000.0, up 224.77%.
  • Retained Earnings for Q4 2025 was $272000.0 at Sarepta Therapeutics, up from $220000.0 in the prior quarter.
  • Over the last five years, Retained Earnings for SRPT hit a ceiling of $2.2 million in Q3 2024 and a floor of -$4.7 billion in Q1 2025.
  • Median Retained Earnings over the past 5 years was -$318500.0 (2023), compared with a mean of -$1.2 billion.
  • Biggest five-year swings in Retained Earnings: crashed 177162800.0% in 2022 and later skyrocketed 451.88% in 2024.
  • Sarepta Therapeutics' Retained Earnings stood at -$20000.0 in 2021, then plummeted by 8220.0% to -$1.7 million in 2022, then soared by 155.17% to $918000.0 in 2023, then plummeted by 123.75% to -$218000.0 in 2024, then skyrocketed by 224.77% to $272000.0 in 2025.
  • The last three reported values for Retained Earnings were $272000.0 (Q4 2025), $220000.0 (Q3 2025), and -$51000.0 (Q2 2025) per Business Quant data.